Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma
Primary Purpose
Primary Open Angle Glaucoma, Ocular Hypertension
Status
Unknown status
Phase
Phase 1
Locations
Italy
Study Type
Interventional
Intervention
Epigallocatechin-gallate
Sponsored by
About this trial
This is an interventional supportive care trial for Primary Open Angle Glaucoma focused on measuring Epigallocatechin-Gallate, Glaucoma, Optic Nerve, Pattern Electroretinogram, Retinal Ganglion Cells
Eligibility Criteria
Inclusion Criteria:
- IOP > 21 mmHg at the time of diagnosis
- Response to ipotensive therapy
- No visible alterations of the optical nerve head (if OHT)
- Visual field: normal (if OHT), < -6dB at diagnosis (if POAG)
- Alterations in PERG
- Familiarity for glaucoma (if OHT)
Exclusion Criteria:
- Change of ipotensive therapy
- Ocular surgery
- Other ocular pathologies
- Smokers
Sites / Locations
- Catholic University, Policlinico A. Gemelli (Hospital)Recruiting
Outcomes
Primary Outcome Measures
PERG
Secondary Outcome Measures
IOP
Optical Coherence Tomography measurements of retinal nerve fiber layer thickness
Full Information
NCT ID
NCT00476138
First Posted
May 18, 2007
Last Updated
May 18, 2007
Sponsor
Catholic University of the Sacred Heart
1. Study Identification
Unique Protocol Identification Number
NCT00476138
Brief Title
Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma
Official Title
Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma
Study Type
Interventional
2. Study Status
Record Verification Date
May 2007
Overall Recruitment Status
Unknown status
Study Start Date
November 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2008 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Catholic University of the Sacred Heart
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The present study attempts to evaluate the potential beneficial effects of a flavonoid, the epigallocatechingallate, on retinal ganglion cell function, evaluated by pattern electroretinogram, in subjects with ocular hypertension or early glaucoma.
Detailed Description
Twenty ocular hypertension and twenty early open angle glaucoma patients will be randomly divided into two groups: 1. placebo group [ocular hypertension, n = 10, early glaucoma (n=10)], taking an oral placebo in addition to standard beta-blocker treatment for ocular hypertension; 2. Treatment group [ocular hypertension, n = 10, early glaucoma (n=10)], taking Epigallocatechingallate oral treatment (200 mg/day) in addition to standard beta-blocker treatment for ocular hypertension. The patients will undergo standard clinical examination including automated Humphrey perimetry (30-2), pattern electroretinogram recording and measurement of retinal nerve fiber layer thickness by Optical Coherence Tomography (OCT stratus) at baseline, 3 and 6 months of treatment and follow-up. All patients will be again tested at 3 and 6 months after changing, in a cross-over design, placebo with drug assumption and vice versa.
Main outcome measure will be pattern electroretinogram amplitude. Secondary measures will be Humphrey perimetry mean deviation and corrected pattern standard deviation, and the thickness of optic nerve fibers measured by OCT.
Pattern Electroretinogram recordings.
Stimuli will be horizontal gratings of 1.6 cycles/degree spatial frequency, modulated in counterphase at 8.14 Hz and electronically generated on a high-resolution TV monitor (contrast: 70%; mean luminance: 80 cd/m2; field size: 31° [width] x 24° [height]). Subjects fixate at the center of the stimulating field with natural pupils, whose size will be measured, at a viewing distance of 57 cm. The subjects or patients will wear full refractive correction for the test distance. Signals will be recorded by a standard, flat-cup, 9 mm Ag/AgCl electrode taped on the skin of the lower eyelid. A similar electrode, placed over the eyelid of the contralateral, unstimulated eye, will be used as reference. Responses will be amplified (100, 000), bandpass filtered (1-30 Hz), sampled with a resolution of 12 bits and averaged (250 events) with automatic artifact rejection. Two replications will be obtained for each record to verify reproducibility. Peak-to-peak amplitude (in microV) of the Fourier analyzed response 2nd harmonic will be measured.
Retinal Nerve Fiber Thickness by OCT
All patients will undergo OCT imaging (software version 4.0.1, Carl Zeiss Meditec Ophthalmic Systems Inc, Dublin, CA) of the peripapillary RNFL. The instrument will be properly aligned after the subjects are comfortably seated with their head and chin firmly positioned against the relative rests. The OCT lens will be adjusted for the patient's refractive error. The subject will be instructed to stare at the internal fixation target with the eye under examination, to enable the optic disc to come into the window and to be successively centered. The Z-offset and the polarization will be adjusted to optimize the axial interval to the OCT scan and to maximize the reflective signal, respectively. The scan protocol will be the fast RNFL thickness 3.4 (3 circular scans consecutively performed, each 3.46 mm in diameter, centered on the optic disc and averaged to form a mean baseline). All scans will be acquired five times per eye during the same day, with short breaks between measurements, under dark room conditions. Images with eye movements during scans, poor centration, poor focus, or a signal strength less than 7/10 were excluded. The mean of 3 separate RNFL measurements (256 A-scans each) with the best optic disc centration, reproducibility of the signal profiles and signal strength will be used. Retinal thickness will be measured with the location of the vitreoretinal interface and the retinal pigment epithelium defining the inner and outer boundaries of the retina, respectively. The boundaries of the RNFL will be defined by first determining the thickness of the neurosensory retina. The location of the posterior boundary of the RNFL will be determined by evaluating each A-scan for a threshold chosen to be 15 dB greater than the filtered maximum reflectivity of the adjacent retina. Various machine-generated parameters will be used for evaluation of RNFL thickness, including RNFL average thickness over the entire cylindrical section and average RNFL thickness in each quadrant (inferior, superior, temporal and nasal). Abnormal RNFL measurements using OCT will be defined as mean or quadrantic thickness values outside 95% normal limits, based on the instrument's normative age-matched database, that will be confirmed on at least three out of five repeat scans. The reference values obtained from the normal control group included in the study will be also considered. The average RNFL thickness, inferior RNFL thickness, and the superior RNFL thickness have been shown to be the best discriminators for glaucoma by the Stratus OCT. These three measures will be the RNFL parameters analyzed in our study. One author (DM) will perform all the image acquisitions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Open Angle Glaucoma, Ocular Hypertension
Keywords
Epigallocatechin-Gallate, Glaucoma, Optic Nerve, Pattern Electroretinogram, Retinal Ganglion Cells
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Epigallocatechin-gallate
Primary Outcome Measure Information:
Title
PERG
Time Frame
six months
Secondary Outcome Measure Information:
Title
IOP
Time Frame
six months
Title
Optical Coherence Tomography measurements of retinal nerve fiber layer thickness
Time Frame
six months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
IOP > 21 mmHg at the time of diagnosis
Response to ipotensive therapy
No visible alterations of the optical nerve head (if OHT)
Visual field: normal (if OHT), < -6dB at diagnosis (if POAG)
Alterations in PERG
Familiarity for glaucoma (if OHT)
Exclusion Criteria:
Change of ipotensive therapy
Ocular surgery
Other ocular pathologies
Smokers
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Benedetto Falsini, M.D.
Phone
01139-06-3015
Ext
6344
Email
bfalsini@rm.unicatt.it
First Name & Middle Initial & Last Name or Official Title & Degree
Emilio Balestrazzi, M.D.
Phone
01139-06-3015
Ext
4929
Email
emilio.balestrazzi@rm.unicatt.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benedetto Falsini, MD
Organizational Affiliation
Chatolic University of Sacred Heart, Roma
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tommaso Salgarello, M.D.
Organizational Affiliation
Catholic University, Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dario Marangoni, M.D.
Organizational Affiliation
Catholic University, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Catholic University, Policlinico A. Gemelli (Hospital)
City
Rome
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benedetto Falsini, M.D.
Phone
01139-06-3015
Ext
4929
Email
icloc@rm.unicatt.it
12. IPD Sharing Statement
Citations:
PubMed Identifier
10440253
Citation
Salgarello T, Colotto A, Falsini B, Buzzonetti L, Cesari L, Iarossi G, Scullica L. Correlation of pattern electroretinogram with optic disc cup shape in ocular hypertension. Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1989-97.
Results Reference
background
PubMed Identifier
10892864
Citation
Colotto A, Falsini B, Salgarello T, Iarossi G, Galan ME, Scullica L. Photopic negative response of the human ERG: losses associated with glaucomatous damage. Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2205-11.
Results Reference
background
PubMed Identifier
19290537
Citation
Falsini B, Marangoni D, Salgarello T, Stifano G, Montrone L, Di Landro S, Guccione L, Balestrazzi E, Colotto A. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram. Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1223-33. doi: 10.1007/s00417-009-1064-z. Epub 2009 Mar 17.
Results Reference
derived
Learn more about this trial
Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma
We'll reach out to this number within 24 hrs